Latest Breaking News On - Innovation of the university - Page 3 : comparemela.com

Published: Apr 13, 2021 beLAB2122 LEVERAGES ACADEMIC INNOVATION FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY EVOTEC PROVIDES ITS ALL-MODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC PROJECTS FROM THE UNIVERSITIES OF FRANKFURT, HEIDELBERG AND TÜBINGEN AS WELL AS FROM THE EMBL AND THE DKFZ BRISTOL MYERS SQUIBB TO PROVIDE FUNDING AND COMMERCIAL PERSPECTIVES FOR ACADEMIC ASSETS DEVELOPED BY beLAB2122 HAMBURG, GERMANY / / April 13, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

Baden wubergUnited statesPeter grathwohlRhein neckarManfred schubert zsilaveczWerner lanthalerThomas hankeMatthias hentzeVolker braunRainer wesselRupert vesseyMatthias weidemGabriele hansenInnovation development generation efficiencyBoehringer ingelheimBristol myers squibb company